The role of MALAT1 and UCA1 long non-coding RNAs on the prognosis of patients with glioblastoma: A systematic review and meta-analysis

Abstract

Glioblastoma multiforme (GBM) is a common central nervous system malignancy with poor survival despite new treatments. Although some evidence demonstrated the prognostic effects of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and urothelial carcinoma associated 1 (UCA1) long non-coding RNAs (lncRNAs) in patients with GBM, a comprehensive study has not yet evaluated the clinical importance of these lncRNAs. Hence, this review aimed to predict the significance of expressions of MALAT and UCA1 lncRNAs in patients with GBM. Using proper keywords, a thorough literature search was performed via databases, including PubMed, Web of Knowledge, Scopus, and EMBASE until December 2024. The relationship between lncRNA expressions and overall survival (OS) in patients with GBM was assessed using hazard ratios (HR) and confidence intervals (95% CI), and the fixed and random effects models were used to estimate the pooled effect size. Also, the Newcastle-Ottawa Quality Assessment Scale was used as an appraisal tool. Among 1553 initially founded records, 13 studies were enrolled in the final analysis, consisting of 915 and 257 samples in the MALAT1 and UCA1 groups, respectively. Compared to the patients with low expression, those with high expression of MALAT1 had a mortality risk of 80% (HR = 1.8, 95% CI = [1.39, 2.33], p = .001). Additionally, the impact of UCA1 expression on patient prognosis indicated that lower OS among patients was correlated with high expression of UCA1; however, the meta-analysis was not performed for UCA1 due to a lack of adequate studies. According to our findings, high expression of MALAT1 was correlated with poor prognosis in patients with GBM.

Keywords

glioblastoma multiform / long non-coding RNA / MALAT / survival / UCA1

References

[1] Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016; 20(5 Suppl): S2-S8.

[2] Mao H, Lebrun DG, Yang J, Zhu VF, Li M. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012; 30(1): 48-56.

[3] Shi J, Dong B, Cao J, et al. Long non-coding RNA in glioma: signaling pathways. Oncotarget. 2017; 8(16): 27582-27592.

[4] Luo C, Xu S, Dai G, Xiao Z, Chen L, Liu Z. Tumor treating fields for high-grade gliomas. Biomed Pharmacother. 2020; 127: 110193.

[5] Noori-Daloii MR, Eshaghkhani Y. lncRNAs roles in cancer occurrence. Med Sci J Islam Azad Univ. 2015; 25(3): 163-182.

[6] Zhang R, Xia LQ, Lu WW, Zhang J, Zhu JS. LncRNAs and cancer. Oncol Lett. 2016; 12(2): 1233-1239.

[7] Bin X, Hongjian Y, Xiping Z, Bo C, Shifeng Y, Binbin T. Research progresses in roles of LncRNA and its relationships with breast cancer. Cancer Cell Int. 2018; 18: 179.

[8] Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G, Zhu YS. MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018; 10: 6757-6768.

[9] Liu JH, Chen G, Dang YW, Li CJ, Luo DZ. Expression and prognostic significance of lncRNA MALAT1 in pancreatic cancer tissues. Asian Pac J Cancer Prev. 2014; 15(7): 2971-2977.

[10] Chen W, Xu XK, Li JL, et al. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget. 2017; 8(14): 22783-22799.

[11] Xin H, Liu N, Xu X, et al. Knockdown of lncRNA-UCA1 inhibits cell viability and migration of human glioma cells by miR-193a-mediated downregulation of CDK6. J Cell Biochem. 2019; 120(9): 15157-15169.

[12] Zhou Q, Liu J, Quan J, Liu W, Tan H, Li W. lncRNAs as potential molecular biomarkers for the clinicopathology and prognosis of glioma: a systematic review and meta-analysis. Gene. 2018; 668: 77-86.

[13] Piri S, Ghodsi Z, Shool S, et al. Macrophage migration inhibitory factor as a therapeutic target after traumatic spinal cord injury: a systematic review. Eur Spine J. 2021; 30: 1474-1494.

[14] Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One. 2016; 11(1): e0147601.

[15] Li ZG, Xiang WC, Shui SF, Han XW, Guo D, Yan L. 11 long noncoding RNA UCA1 functions as miR-135a sponge to promote the epithelial to mesenchymal transition in glioma. J Cell Biochem. 2019; 121(3): 2447-2457.

[16] Ak Aksoy S, Mutlu M, Tunca B, et al. Coexistence of TERT C228T mutation and MALAT1 dysregulation in primary glioblastoma: new prognostic and therapeutic targets. Neurol Res. 2021; 43(11): 916-925.

[17] He Z, Wang Y, Huang G, Wang Q, Zhao D, Chen L. The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP. Arch Biochem Biophys. 2017; 623-624: 1-8.

[18] Ma KX, Wang HJ, Li XR, et al. Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma. Tumor Biol. 2014; 36(5): 3355-3359.

[19] Argadal OG, Mutlu M, Ak Aksoy S, et al. Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas. Bosn J Basic Med Sci. 2020; 20(1): 63-69.

[20] Cheng H, Zhao H, Xiao X, et al. Long non-coding RNA MALAT1 upregulates ZEB2 expression to promote malignant progression of glioma by attenuating miR-124. Mol Neurobiol. 2020; 58(3): 1006-1016.

[21] Fawzy MS, Toraih EA, Abdallah HY. Long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1): a molecular predictor of poor survival in glioblastoma multiforme in Egyptian patients. Egypt J Med Hum Genet. 2017; 18(3): 231-239.

[22] Zhao W, Sun C, Cui Z. A long noncoding RNA UCA1 promotes proliferation and predicts poor prognosis in glioma. Clin Transl Oncol. 2016; 19(6): 735-741.

[23] Sun Y, Jin JG, Mi WY, et al. Long noncoding RNA UCA1 targets miR-122 to promote proliferation, migration, and invasion of glioma cells. Oncol Res. 2018; 26(1): 103-110.

[24] Shen J, Hodges TR, Song R, et al. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog. 2018; 57(1): 137-141.

[25] Xiang JP, Guo SF, Jiang SL, et al. Silencing of long non-coding RNA MALAT1 promotes apoptosis of glioma cells. J Korean Med Sci. 2016; 31(5): 688-694.

[26] Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. Am J Cancer Res. 2016; 6(11): 2561-2574.

[27] Yang G, Lu X, Yuan L. LncRNA: a link between RNA and cancer. Biochim Biophys Acta. 2014; 1839(11): 1097-1109.

[28] Fan XN, Zhang SW. lncRNA-MFDL: identification of human long non-coding RNAs by fusing multiple features and using deep learning. Mol Biosyst. 2015; 11(3): 892-897.

[29] Wu S, Lin Y, Xu D, et al. MiR-135a functions as a selective killer of malignant glioma. Oncogene. 2012; 31(34): 3866-3874.

[30] Ding C-Q, Deng W-S, Yin X-F, Ding X-D. MiR-122 inhibits cell proliferation and induces apoptosis by targeting runt-related transcription factors 2 in human glioma. Eur Rev Med Pharmacol Sci. 2018; 22(15): 4925-4933.

[31] Tabuse M, Ohta S, Ohashi Y, et al. Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Mol Cancer. 2011; 10: 60.

[32] Tani H, Nakamura Y, Ijiri K, Akimitsu N. Stability of MALAT-1, a nuclear long non-coding RNA in mammalian cells, varies in various cancer cells. Drug Discov Ther. 2010; 4(4): 235-239.

[33] Xiaoling T, Guoxiong X. Clinical value of lncRNA MALAT1 as a prognostic marker in human cancer: systematic review and meta-analysis. BMJ Open. 2015; 5(9): e008653.

[34] Liao K, Lin Y, Gao W, et al. Blocking lncRNA MALAT1/miR-199a/ZHX1 axis inhibits glioblastoma proliferation and progression. Mol Ther Nucleic Acids. 2019; 18: 388-399.

[35] Li ZJ, Xu CY, Ding BQ, Gao M, Wei XT, Ji N. Long non-coding RNA MALAT1 promotes proliferation and suppresses apoptosis of glioma cells through derepressing Rap1B by sponging miR-101. J Neurooncol. 2017; 134(1): 19-28.

[36] Kim SS, Harford JB, Moghe M, Rait A, Pirollo KF, Chang EH. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res. 2018; 46(3): 1424-1440.

[37] Han Y, Wu Z, Wu T, et al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling. Cell Death Dis. 2016; 7: e2123.

RIGHTS & PERMISSIONS

2025 The Author(s). Precision Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital.